OncoMatch/Clinical Trials/NCT06757153
Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients
Is NCT06757153 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies NRG-103 for glioblastoma (gbm).
Treatment: NRG-103 — The goal of this clinical trial is to learn if NRG103 works to treat recurrent GBM in adults. It will also learn about the safety of NRG103. The main questions it aims to answer are: Does NRG103 prolong overall survival or disease-free survival in patients with GBM? What medical problems do participants have when receiving NRG103 treatment? Researchers will give patients with NRG103 to see if NRG103 works to treat recurrent GBM. Participants will: Receive NRG103 twice in 14 days Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: anti-tumor treatment
Patients have experienced recurrence (RANO 2.0) after previous anti-tumor treatments, including the recurrent tumor has been surgically removed and an Ommaya reservoir has been placed inside the tumor cavity.
Must have received: surgery — recurrent tumor
the recurrent tumor has been surgically removed
Must have received: Ommaya reservoir placement — tumor cavity
an Ommaya reservoir has been placed inside the tumor cavity
Cannot have received: cell therapy
A history of cell therapy
Cannot have received: gene therapy
A history of gene therapy
Cannot have received: oncolytic virus therapy
A history of oncolytic virus therapy
Cannot have received: anti-tumor vaccines
A history of anti-tumor vaccines or other immunomodulatory drugs with 4 weeks
Cannot have received: immunomodulatory drugs
A history of anti-tumor vaccines or other immunomodulatory drugs with 4 weeks
Lab requirements
Blood counts
White blood cell count>2.0 × 10^9/L, neutrophil count>1.0 × 10^9/L, platelet count>100 × 10^9/L, international normalized ratio ≤1.5 times ULN, and activated partial thromboplastin time≤1.5 times ULN
Kidney function
Normal renal function
Liver function
Normal liver function
Cardiac function
Normal heart function
Adequate bone marrow reserve: White blood cell count>2.0 × 10^9/L, neutrophil count>1.0 × 10^9/L, platelet count>100 × 10^9/L, international normalized ratio ≤1.5 times ULN, and activated partial thromboplastin time≤1.5 times ULN. Normal heart, renal and liver function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify